Avetik Muradyan

Avetik Muradyan

Auto-generated profile, based on publicly available information

Avetik Muradyan

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
AКArray А. Костин
Array А. Костин
NVN. V. Vorobyev
N. V. Vorobyev
AТArray О. Толкачев
Array О. Толкачев
AMA. G. Muradyan
A. G. Muradyan
SPS. V. Popov
S. V. Popov
РЕЗУЛЬТАТЫ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ БОЛЬНЫХ ОПУХОЛЯМИ НАДПОЧЕЧНИКОВ

9 September 2018 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
HGH. S. Gevorgyan
H. S. Gevorgyan
AKA. A. Kostin
A. A. Kostin
NVN. V. Vorobyev
N. V. Vorobyev
KNK. М. Nyushko
K. М. Nyushko
AMA. G. Muradyan
A. G. Muradyan
YSY. V. Samsonov
Y. V. Samsonov
Providing a high quality of life for a man after performing radical prostatectomy for prostate cancer is currently one of the topical problems of urology and andrology. Nervous-protective radical prostatectomy is one of the high-tech operations in urology and the surgeon’s task is not only to remove the tumor of the prostate gland, but also to ensure a high quality of life for the patient. The importance and urgency of this problem is evidenced by the fact that most of the issues that arise in patients in conversation with a surgeon before surgical intervention are devoted to it.The National Institute of Health of the USA shows that the incidence of prostate cancer is about 9.5% per year, and the localized form began to occur in younger men. In this regard, the surgeon faces the task not only to cure the patient of malignant education, but also to maintain the erectile function and the continent’s indicators, thereby improving the quality of life.At the present stage, diagnostic methods make it possible to detect early prostate cancer much more often, so that the identification and treatment of such patients become more accessible and allows the use of this operation. However, for the preservation of the neurovascular bundle, it is mandatory to know the anatomical features of this zone.Over the past few decades, anatomical studies have been conducted that described the neuroanatomy of the prostate and the adjacent tissue. This article summarizes the latest results of studies of neuroanatomical studies, some of which contradict the established consensus on pelvic anatomy.

1 January 2017 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
AKA. A. Kostin
A. A. Kostin
AMA. G. Muradyan
A. G. Muradyan
ATA. O. Tolkachev
A. O. Tolkachev
SPS. V. Popov
S. V. Popov
РАДИЙ-223. МЕСТО В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО КАСТРАЦИОННО-РЕФРАКТЕРНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

9 December 2022 in Cancer Urology
Verified
Journal Article
Open access
PDF file
OKO. B. Karyakin
O. B. Karyakin
NVN. V. Vorobyov
N. V. Vorobyov
IZI. N. Zaborskiy
I. N. Zaborskiy
AMA. G. Muradyan
A. G. Muradyan
KSK. N. Safiullin
K. N. Safiullin
AKAndrei Kaprin
Andrei Kaprin
Background. Bladder cancer is the ninth most common malignant neoplasm worldwide. Hidden metastases at the time of diagnosis are the main reason muscle-invasive bladder cancer has poor prognosis. Even after radical cystectomy, muscleinvasive bladder cancer mostly progresses within 2 years with a recurrence rate of over 50 %. At stages II–IV of the disease, drug treatment is indicated before radical cystectomy. The main goal of neoadjuvant chemotherapy is to affect micrometastases, which may be present at the beginning of disease development. The response to ongoing chemotherapy can serve as a predictor of long-term survival.Aim. To increase effectiveness of bladder cancer treatment.Materials and methods. A total of 231 patients with bladder cancer were included in the study. The main contingent consisted of men over 60 years old with locally advanced tumors at stage Т2–Т4. Drug therapy was carried out in neoadjuvant mode before surgical treatment. Standard regimens were used: cisplatin + gemcitabine and MVAC (methotrexate, vinblastine, adriamycin, cisplatin). After four courses of neoadjuvant chemotherapy, the results were evaluated. With complete normalization of a patient’s condition, the issue of surgical treatment – radical cystectomy with one of the types of urinary diversion – was decided.Results and conclusion. The follow-up period for patients after treatment was 62 months. In patients who underwent neoadjuvant chemotherapy, the median overall survival was 44.9 months, in patients without neoadjuvant treatment – 36.8 months with improvement in recurrence-free survival from 32.5 to 39.8 months (p = 0.08). Overall survival after neoadjuvant chemotherapy improved by 8.1 months (p = 0.09).

24 December 2019 in Archiv Euromedica
Verified
Journal Article
Closed access
AMAvetik Muradyan
Avetik Muradyan
AKAndrei Kostin
Andrei Kostin
ATAleksandr Tolkachev
Aleksandr Tolkachev
NVNikolay Vorobyev
Nikolay Vorobyev

2 September 2020 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
AMA. G. Muradyan
A. G. Muradyan
AKA. A. Kostin
A. A. Kostin
ATA. O. Tolkachev
A. O. Tolkachev
NVN. V. Vorobyev
N. V. Vorobyev
ХИРУРГИЧЕСКОЕ ЛЕЧЕНИЕ СОЛИТАРНОГО МЕТАСТАТИЧЕСКОГО ПОРАЖЕНИЯ НАДПОЧЕЧНИКА ПРИ НЕМЕЛКОКЛЕТОЧНОМ РАКЕ ЛЕГКОГО